| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | Recombinant full-length human BPIFB1/LPLUNC1 protein was used as the immunogen for the BPIFB1 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
The upper respiratory tract is the main place of entry for pathogens to invade the body, and early recognition of bacterial products in this region is crucial for host defense. Palate lung nasal epithelial clone PLUNC (or LUNX) is an airway specific secretory protein that is expressed in epithelial tissues and submucosal glands of the oral cavity and upper respiratory tract of humans, mice, rats and cows. PLUNC binds to lipopolysaccharide (LPS) in nasal lavage fluid (NLF) which points to its role in the inflammatory response of the upper airways after exposure to irritants. Decreased levels of PLUNC occur in the NLF of smokers and people who have been exposed to reactive epoxy chemicals, indicating that long-term exposure to airway irritants impairs the production of PLUNC in the upper respiratory tract. Abnormal expression of PLUNC may influence susceptibility to nasopharyngeal carcinoma in the Chinese population.
This anti-LPLUNC1 antibody is supplied as Purified (Mouse, Monoclonal (mouse origin), clone LPLUNC1/3206, Mouse IgG, Unconjugated) and is designed to support common target-detection workflows after the on-page specifications.
Key elements and design rationale
- Target: LPLUNC1
- Format: Purified
- Localization: Secreted
- Species reactivity: Human
- Applications (listed): ELISA, WB, IHC-P
- Conjugate: Unconjugated
- Clone and antibody class: Monoclonal (mouse origin), clone LPLUNC1/3206, Mouse IgG
Because antibody performance can depend on epitope context, sample preparation, and biological state, interpret signals using appropriate controls and orthogonal evidence when possible.
Biological background
LPLUNC1 is referenced in public gene/protein resources (e.g., UniProt and NCBI Gene), which provide curated names/synonyms, protein features, and pathway context. When designing assays, consider potential isoforms, post-translational modifications, and cell-type specific expression that may influence observed signal.
Research relevance and current trends
- Profiling LPLUNC1 expression across model systems, perturbations, and time points to support mechanistic hypotheses.
- Combining antibody-based detection with multi-omics or imaging readouts to link LPLUNC1 signal with phenotype.
- Using well-matched controls (isotype controls, genetic perturbations, or independent reagents) to strengthen interpretation of target-associated signal.
Common research applications
- ELISA
- WB
- IHC-P
Use the listed applications as a starting point and tailor experimental design to your sample type and readout requirements.
Notes for experimental interpretation
- Specificity considerations: closely related family members, isoforms, or PTMs can affect apparent specificity; confirm with independent approaches when critical.
- Controls: include negative controls and, when feasible, genetic or pharmacologic perturbations to support target attribution in your system.
- Species and sample context: differences in sequence, expression, fixation, or extraction conditions can change signal behavior across models.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.